FASLG and neoplasm: Interestingly, although CD95L (FasL/CD178)-expressing immune cells edit tumor cells by sparing cells expressing low CD95 (Fas/APO-1) level at their plasma membrane (Strasser et al., 2009), the complete loss of CD95 is deleterious to tumor growth (Chen et al., 2010).